Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on September 5, 2013, covering events occurring between August 29, 2013, and September 5, 2013. The company is a Delaware corporation focused on the development and commercialization of pharmaceutical products.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes and Events
- Commercial Launch: On September 5, 2013, the company announced that Trokendi XR, a novel once-daily extended-release formulation of topiramate for the treatment of epilepsy, is now available to patients in the United States.
- Market Distribution: The product has been shipped to major wholesalers, and the company's sales force has begun promoting the product to physicians.
- Investor Relations: On August 29, 2013, management announced plans to present an overview of the company at investor conferences on September 9, 2013, and September 12, 2013.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, quantitative outlooks, or detailed risk factors. The primary outlook is the immediate commercial availability of Trokendi XR and the upcoming management presentations to investors.
Key Facts for Investor Verification
- Confirm the commercial launch status and initial market uptake of Trokendi XR.
- Review the content of the press releases attached as Exhibits 99.1 and 99.2 for further details on the product and investor conference presentations.
- Monitor upcoming investor conference presentations scheduled for September 9 and 12, 2013, for management commentary on the launch.